A 5-year study conducted in Germany showed only 7% of adults and 8% of children with severe anaphylaxis received epinephrine.
Your daily dose of the clinical news you may have missed.
Among pediatric patients aged 1 month to 18 years with emergent anaphylaxis, cephalosporins were the leading antibiotics and ibuprofen the top NSAID implicated in a new study.
Your daily dose of the clinical news you may have missed.
Your daily dose of the clinical news you may have missed.
Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.
The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.
Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.
Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.
If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.